Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Julius Simon

Pediatrics New Hartford, NY Medical Doctor

NPI 1952395006 CMS profile 270583

1729 Burrstone Rd, New Hartford, NY 13413

Open in the dashboard

General payments

$2,301

135 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Julius Simon of New Hartford, NY is reported in the CMS Open Payments database as having received $2,301 across 135 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $488 23
2023 General $523 28
2022 General $726 51
2021 General $137 7
2020 General $118 8
2019 General $309 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Julius Simon
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Julius Simon were reported at $0. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Julius Simon Pediatrics median Middle half National median
2019 $309 $86 $31–$183 $163
2020 $118 $49 $22–$110 $114
2021 $137 $68 $27–$158 $132
2022 $726 $77 $30–$173 $149
2023 $523 $88 $33–$190 $160
2024 $488 $94 $34–$206 $164
2025 $0 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Merck Sharp & Dohme Corporation $427 24 payments
  2. Ironshore Pharmaceuticals Inc. $407 19 payments
  3. Supernus Pharmaceuticals, Inc. $265 25 payments
  4. Corium, Inc. $248 15 payments
  5. GlaxoSmithKline, LLC. $178 11 payments
  6. Sanofi Pasteur Inc. $133 6 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $100 5 payments
  8. Seqirus USA Inc $99 5 payments
  9. Pfizer Inc. $88 5 payments
  10. Tris Pharma Inc $50 3 payments
  11. Other $304 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $2,294 134 payments
  2. Education $7 1 payment
Products named General payments · program years 2019–2024
  1. GARDASIL 9 $359 20 payments
  2. VAXELIS $255 14 payments
  3. Azstarys $248 15 payments
  4. JORNAY PM Central Nervous System Stimulant $247 11 payments
  5. VAXNEUVANCE $220 11 payments
  6. QELBREE $220 23 payments
  7. ROTATEQ $206 12 payments
  8. BEXSERO $178 11 payments
  9. PEDIARIX $162 10 payments
  10. JORNAY PM Central Nervous Stimulant ADHD $120 6 payments
  11. Other $1,721 92 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

135 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record